These elements could support stock performance in the year ahead ... Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.

Lombardi claims the new era of UNC football is resonating with grad transfers and their agents. "If you're a grad transfer that is ... year and improve your stock? What's the best way to improve ...

Eli Lilly ( LLY 3.89%) stock inched 2.5% higher through 9:50 a.m. ET Thursday after beating on the top and bottom lines in ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

According to Benzinga Pro, Eli Lilly's peer group average for short interest as a percentage of float is 4.12%, which means ...

Analysts are bullish on the maker of weight-loss drugs Zepbound and Mounjaro, with 10 of the 11 analysts who follow the company and are tracked by Visible Alpha rating Eli Lilly stock as a "buy ...

Aaron McDade is a breaking news reporter for Investopedia. He is an experienced journalist who has covered everything from the latest in business and tech news to sports and international news ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $13.72 billion ...

This would not only drive sales growth but also reinforce Eli Lilly's position as an innovator in the metabolic disease space, potentially leading to increased investor confidence and stock ...